Satavaptan
Satavaptan is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vasopressin V1a receptor, vasopressin V2 receptor, and vasopressin V1b receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 3 | 3 | — | — | 6 |
| Ascites | D001201 | HP_0001541 | R18 | — | 3 | 3 | — | — | 6 |
| Inappropriate adh syndrome | D007177 | EFO_1000982 | E22.2 | — | 1 | 3 | — | — | 4 |
| Hyponatremia | D007010 | HP_0002902 | E87.1 | — | 1 | 3 | — | — | 4 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SATAVAPTAN |
| INN | satavaptan |
| Description | Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009.
|
| Classification | Small molecule |
| Drug class | aptamers, classical and mirror; vasopressin receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1ccc2c(c1)[C@]1(CC[C@H](CCN3CCOCC3)CC1)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 185913-78-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107777 |
| ChEBI ID | — |
| PubChem CID | 9810773 |
| DrugBank | DB14923 |
| UNII ID | AJS8S3P31H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
AVPR1A
AVPR1A
AVPR2
AVPR2
AVPR1B
AVPR1B
Organism
Homo sapiens
Gene name
AVPR1A
Gene synonyms
AVPR1
NCBI Gene ID
Protein name
vasopressin V1a receptor
Protein synonyms
Antidiuretic hormone receptor 1a, AVPR V1a, SCCL vasopressin subtype 1a receptor, V1-vascular vasopressin receptor AVPR1A, V1a vasopressin receptor, Vascular/hepatic-type arginine vasopressin receptor
Uniprot ID
Mouse ortholog
Avpr1a (54140)
vasopressin V1a receptor (Q9QYH2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 206 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more